On Thursday, U.S. stocks edged higher.
The number of people seeking U.S. unemployment benefits rose last week to the highest level since May, though the pace of applications remains at a level consistent with steady hiring. Weekly applications rose 7,000 to a seasonally adjusted 320,000, the Labor Department said Thursday. The four-week average, a less volatile measure, raised 10,250 to 304,750, a six-week high.
Insights about U.S. Stocks that are active during the current trade, are depicted underneath:
Zynga Inc (NASDAQ:ZNGA)’s shares picked up 0.84%, and is now trading at $2.41. The Stock is active as 2.60M shares changed hands versus its average volume of 17.13M shares.
Formerly on February 25, Zynga Inc. (ZNGA) declared that Chief Executive Officer Don Mattrick will present at the Morgan Stanley Technology, Media & Telecom Conference in San Francisco on Thursday, March 5, 2015. The presentation is planned to start at 9:55 a.m. Pacific Standard Time and will be accessible through a webcast, accessible on the Zynga Investor Relations website at http://investor.zynga.com. A replay will also be accessible on Zynga’s Investor Relations website following the event.
Zynga Inc. is a leading developer of the world’s most popular social games that are played by more than 100 million monthly consumers. The corporation has created evergreen franchises such as FarmVille, Zynga Casino and Words With Friends.
Denbury Resources Inc (NYSE:DNR), dipped -2.45%, and is now trading at $8.35. The Stock is active as 4.67M shares changed hands versus its average volume of 14.27M shares.
Formerly On February 19, Denbury Resources Inc. (DNR) declared adjusted net revenue (a non-GAAP measure) of $93 million for the fourth quarter of 2014, or $0.27 per diluted share. On a GAAP basis, the Corporation recorded quarterly net revenue of $364 million, or $1.04 per diluted share, on quarterly proceeds of $480 million. Adjusted net revenue for the fourth quarter of 2014 differs from GAAP net revenue primarily due to the exclusion of a $451 million (pre-tax) gain on noncash fair value adjustments on commodity derivatives (a non-GAAP measure)(1).
Phil Rykhoek, Denbury’s President and CEO, commented, “The noteworthy decrease in global oil prices during the second half of 2014 and early 2015 have influenced the entire industry. However, we have seen this happen before and therefore we have taken what we believe are prudent and proactive measures in this uncertain price environment to preserve our liquidity and financial strength, such as our earlier decisions to reduce 2015 capital spending by about 50% and to maintain our dividend rate at the same level as in 2014. As we look back upon 2014, we see a year in which oil prices reached $107 per barrel (“Bbl”) mid-year, then proceeded to fall over 50% by year end, and further to the mid-$40 per barrel range in the new year. The magnitude of this price drop in such a short period of time obviously presents many challenges in planning for both our near-term and long-term development projects. We believe that our adjustments to capital and dividends, coupled with Denbury’s strong hedge position, will generate more than adequate cash flows to cover capital expenditures and dividends in 2015 at current strip prices.
Denbury’s 2015 Annual Meeting of Stockholders will be held on Tuesday, May 19, 2015, at 3:00 P.M. (Central), at Denbury’s corporate offices located at 5320 Legacy Drive, Plano, Texas. The record date for determination of shareholders entitled to vote at the annual meeting is the close of business on Tuesday, March 24, 2015.
Denbury Resources Inc. operates as an oil and natural gas corporation in the United States. The corporation primarily focuses on improved oil recovery utilizing carbon dioxide.
Exxon Mobil Corporation (NYSE:XOM), dropped -0.50%, and is now trading at $86.74. The Stock is active as 4.50M shares changed hands versus its average volume of 14.86M shares.
Exxon Mobil Corporation (XOM), anticipates to start up 16 major oil and natural gas projects during the next three years and is on track to raise daily production to 4.3 million oil-equivalent barrels by 2017, Rex W. Tillerson, chairman and chief executive officer, said recently.
In 2015, ExxonMobil anticipates to raise production volumes 2 percent to 4.1 million oil-equivalent barrels per day, driven by 7 percent liquids growth. The volume raise is supported by the ramp up of several projects accomplished in 2014 and the predictable startup of seven new major developments in 2015, counting Hadrian South in the Gulf of Mexico, expansion of the Kearl project in Canada, Banyu Urip in Indonesia and deepwater expansion projects at Erha in Nigeria and Kizomba in Angola.
In 2016 and 2017, production ramp up is predictable from several projects counting Gorgon Jansz in Australia, Hebron in Eastern Canada and expansions of Upper Zakum in United Arab Emirates and Odoptu in Far East Russia.
ExxonMobil, the largest publicly traded international oil and gas corporation, uses technology and innovation to assist meet the world’s growing energy needs. ExxonMobil holds an industry-leading inventory of resources, is the largest refiner and marketer of petroleum products, and its chemical corporation is one of the largest in the world.
Merck & Co., Inc (NYSE:MRK), enhanced 0.24%, and is now trading at $58.02. The Stock is active as 3.68M shares changed hands versus its average volume of 9.97M shares.
Merck & Co. Inc. (MRK), known as MSD outside the United States and Canada, recently declared results from two post-hoc analyses of the TRA 2°P TIMI 50 (Thrombin Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events) trial of ZONTIVITY® (vorapaxar), one of the largest secondary prevention studies of an antiplatelet medicine. These data on additional endpoints in subgroups of patients with peripheral arterial disease (PAD) are being presented at the 2015 American College of Cardiology (ACC) Scientific Sessions in San Diego from March 14-16, 2015 together with other post-hoc subgroup analyses from the trial, with abstracts presently accessible online.
ZONTIVITY is indicated for the reduction of thrombotic cardiovascular (CV) events in patients with a history of myocardial infarction (MI) or in patients with PAD. The May 2014 U.S. approval of ZONTIVITY was based on the pivotal TRA 2°P TIMI 50 study, in which ZONTIVITY was shown to reduce the rate of a combined endpoint of CV death, MI, stroke and urgent coronary revascularization (UCR) when added to aspirin and/or clopidogrel. The U.S. Prescribing Information for ZONTIVITY comprises a boxed warning regarding bleeding risk, which states that ZONTIVITY is not for use in patients with a history of stroke, transient ischemic attack (TIA) or intracranial hemorrhage (ICH), or active pathological bleeding. Antiplatelet agents, counting ZONTIVITY, raise the risk of bleeding, counting ICH and fatal bleeding.
Merck is a global healthcare leader working to assist the world be well. Merck is known as MSD outside of the United States and Canada.
